Polyethylene Glycol 35 as a perfusate additive for mitochondrial and glycocalyx protection in HOPE liver preservation

dc.contributor.authorPanisello Roselló, Arnau
dc.contributor.authorTeixeira da Silva, Rui
dc.contributor.authorCastro Benítez, Carlos
dc.contributor.authorBardallo, Raquel G.
dc.contributor.authorCalvo Ademuz, Maria
dc.contributor.authorFolch i Puy, Emma
dc.contributor.authorCarbonell i Camós, Teresa
dc.contributor.authorPalmeira, Carlos M.
dc.contributor.authorRoselló Catafau, Juan
dc.contributor.authorAdam, R. (René)
dc.date.accessioned2020-09-15T14:41:32Z
dc.date.available2020-09-15T14:41:32Z
dc.date.issued2020-08-09
dc.date.updated2020-09-15T14:41:33Z
dc.description.abstractOrgan transplantation is a multifactorial process in which proper graft preservation is a mandatory step for the success of the transplantation. Hypothermic preservation of abdominal organs is mostly based on the use of several commercial solutions, including UW, Celsior, HTK and IGL-1. The presence of the oncotic agents HES (in UW) and PEG35 (in IGL-1) characterize both solution compositions, while HTK and Celsior do not contain any type of oncotic agent. Polyethylene glycols (PEGs) are non-immunogenic, non-toxic and water-soluble polymers, which present a combination of properties of particular interest in the clinical context of ischemia-reperfusion injury (IRI): they limit edema and nitric oxide induction and modulate immunogenicity. Besides static cold storage (SCS), there are other strategies to preserve the organ, such as the use of machine perfusion (MP) in dynamic preservation strategies, which increase graft function and survival as compared to the conventional static hypothermic preservation. Here we report some considerations about using PEG35 as a component of perfusates for MP strategies (such as hypothermic oxygenated perfusion, HOPE) and its benefits for liver graft preservation. Improved liver preservation is closely related to mitochondria integrity, making this organelle a good target to increase graft viability, especially in marginal organs (e.g., steatotic livers). The final goal is to increase the pool of suitable organs, and thereby shorten patient waiting lists, a crucial problem in liver transplantation.
dc.format.extent16 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec703211
dc.identifier.issn1661-6596
dc.identifier.pmid32784882
dc.identifier.urihttps://hdl.handle.net/2445/170561
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms21165703
dc.relation.ispartofInternational Journal of Molecular Sciences, 2020, vol. 21, num. 16, p. 5703
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/722619/EU//Foie Gras
dc.relation.urihttps://doi.org/10.3390/ijms21165703
dc.rightscc-by (c) Panisello Rosello, Arnau et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
dc.subject.classificationTrasplantament d'òrgans
dc.subject.otherTransplantation of organs
dc.titlePolyethylene Glycol 35 as a perfusate additive for mitochondrial and glycocalyx protection in HOPE liver preservation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
703211.pdf
Mida:
1.24 MB
Format:
Adobe Portable Document Format